Page last updated: 2024-08-21

isoxazoles and Adenoma

isoxazoles has been researched along with Adenoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clarke, AR; Maughan, TS; Shaw, PH	1
Topol, EJ	1

Other Studies

2 other study(ies) available for isoxazoles and Adenoma

Article	Year
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse. British journal of cancer, 2011, Aug-23, Volume: 105, Issue:5 Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Gefitinib; Genes, APC; Intestinal Neoplasms; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Tumor Burden	2011
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA, 2005, Jan-19, Volume: 293, Issue:3 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoxazoles; Pyrazoles; Sulfonamides; United States; United States Food and Drug Administration	2005

Article

Year

Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.

British journal of cancer, 2011, Aug-23, Volume: 105, Issue:5

Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Gefitinib; Genes, APC; Intestinal Neoplasms; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Tumor Burden

2011

Arthritis medicines and cardiovascular events--"house of coxibs".

JAMA, 2005, Jan-19, Volume: 293, Issue:3

Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoxazoles; Pyrazoles; Sulfonamides; United States; United States Food and Drug Administration

2005